Rosen's Breast Pathology, 4e

407

Ductal Carcinoma In Situ

222. Visscher DW, Wallis TL, Crissman JD. Evaluation of chromosome aneuploidy in tissue sections of preinvasive breast carcinomas using interphase cytogenetics. Cancer 1996;77:315–320. 223. Sarode VR, Han JS, Morris DH, et al. A comparative analysis of bio- marker expression and molecular subtypes of pure ductal carcinoma in situ and invasive breast carcinoma by image analysis: relationship of the subtypes with histologic grade, Ki67, p53 overexpression, and DNA ploidy. Int J Breast Cancer 2011;2011:217060. 224. Stasik CJ, Davis M, Kimler BF, et al. Grading ductal carcinoma in situ of the breast using an automated proliferation index. Ann Clin Lab Sci 2011;41:122–130. 225. Rakovitch E, Nofech-Mozes S, HannaW, et al. HER2/neu andKi-67 ex- pression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ . Br J Cancer 2012;106:1160–1165. 226. Gandhi A, Holland PA, Knox WF, et al. Evidence of significant apop- tosis in poorly differentiated ductal carcinoma in situ of the breast. Br J Cancer 1998;78:788–794. 227. Radford DM, Fair K, Thompson AM, et al. Allelic loss on chro- mosome 17 in ductal carcinoma in situ of the breast. Cancer Res 1993;53:2947–2950. 228. Alburquerque A, Kennedy S, Bryant B, et al. LOH on chromosome 17p and 17q in the histologic spectrum of DCIS. Mod Pathol 1997;10:15A. 229. Lichy JH, Zavar M, Tsai MM, et al. Loss of heterozygosity on chromo- some 11p15 during histological progression in microdissected ductal carcinoma of the breast. Am J Pathol 1998;153:271–278. 230. Chuaqui RF, Zhuang Z, Emmert-Buck MR, et al. Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol 1997;150:297–303. 231. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor sup- pressor gene region. Cancer Res 1996;56:5605–5609. 232. Fujii H, Szumel R, Marsh C, et al. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 1996;56:5260–5265. 233. Stratton MR, Collins N, Lakhani SR, et al. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995;175:195–201. 234. Radford DM, Phillips NJ, Fair KL, et al. Allelic loss and the progres- sion of breast cancer. Cancer Res 1995;55:5180–5183. 235. Munn KE, Walker RA, Varley JM. Frequent alterations of chro- mosome 1 in ductal carcinoma in situ of the breast. Oncogene 1995;10:1653–1657. 236. Zhuang Z, Merino MJ, Chuaqui R, et al. Identical allelic loss on chro- mosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res 1995;55:467–471. 237. James LA, Mitchell ELD, Menasce L, et al. Comparative genomic hy- bridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma. Oncogene 1997;14:1059–1065. 238. Barsky SH, Shao ZM, Bose S. Should DCIS be renamed carcinoma of the ductal system? Breast J 1999;5:70–72. 239. Marsh KL, Varley JM. Loss of heterozygosity at chromosome 9p in ductal carcinoma in situ and invasive carcinoma of the breast. Br J Cancer 1998;77:1439–1447. 240. Aubele M, Mattis A, Zitzelsberger H, et al. Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer 2000;85:82–86. 241. Waldman FM, DeVries S, Chew KL, et al. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 2000;92:313–320. 242. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, et al. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010;57:171–192. 243. Polyak K. Molecular markers for the diagnosis and manage- ment of ductal carcinoma in situ . J Natl Cancer Inst Monogr 2010;2010(41):210–213. 244. Zhou W, Jirström K, Johansson C, et al. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population- based cohort study. BMC Cancer 2010;10:653. 245. Burkhardt L, Grob TJ, Hermann I, et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2010;123:757–765. 246. Schwartz GF, Solin LJ, Olivotto IA, et al. The Consensus Conference on the treatment of in situ ductal carcinoma of the breast, April 22–25, 1999. Hum Pathol 2000;31:131–139.

247. Jackman RJ, Nowels KW, Shepard MJ, et al. Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical cor- relation in lesions with cancer or atypical hyperplasia. Radiology 1994;193:91–95. 248. Liberman L, Dershaw DD, Rosen PP, et al. Stereotaxic core biopsy of breast carcinoma: accuracy at predicting invasion. Radiology 1995;194:379–381. 249. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with direc- tional, vacuum-assisted biopsy. Radiology 1997;202:843–847. 250. Mendez I, Andreu FJ, Saez E, et al. Ductal carcinoma in situ and atypi- cal ductal hyperplasia of the breast diagnosed at stereotactic core bi- opsy. Breast J 2001;7:14–18. 251. Renshaw AA. Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ . Arch Pathol Lab Med 2002;126:39–41. 252. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ under- estimation rates. Radiology 2001;218:497–502. 253. Tuttle TM, Shamliyan T, Virnig BA, et al. The impact of sentinel lymph node biopsy and magnetic resonance imaging on important outcomes among patients with ductal carcinoma in situ . J Natl Cancer Inst Monogr 2010;2010(41):117–120. 254. Dillon MF, Quinn CM, McDermott EW, et al. Diagnostic accuracy of core biopsy for ductal carcinoma in situ and its implications for surgi- cal practice. J Clin Pathol 2006;59:740–743. 255. Dillon MF, Maguire AA, McDermott EW, et al. Needle core biopsy characteristics identify patients at risk of compromised margins in breast conservation surgery. Mod Pathol 2008;21:39–45. 256. Wang HH, Ducatman BS, Eick D. Comparative features of ductal car- cinoma in situ and infiltrating ductal carcinoma of the breast on fine- needle aspiration biopsy. Am J Clin Pathol 1989;92:736–740. 257. Willems SM, van Deurzen CH, van Diest PJ. Diagnosis of breast le- sions: fine-needle aspiration cytology or core needle biopsy? A review. J Clin Pathol 2012;65:287–292. 258. Sneige N, Singletary SE. Fine-needle aspiration of the breast: diagnos- tic problems and approaches to surgical management. Pathol Annu 1994;29(Pt. 1):281–301. 259. Guo HQ, Zhang ZH, Zhao H, et al. Recognizing breast ductal carci- noma in situ on fine-needle aspiration: a diagnostic dilemma. Diagn Cytopathol 2013;41:710–715. 260. McKee GT, Tildsley G, Hammond S. Cytologic diagnosis and grading of ductal carcinoma in situ . Cancer 1999;87:203–209. 261. Lester SC, Bose S, Chen YY, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 2009;133:15–25. 262. Saqi A, Osborne MP, Rosenblatt R, et al. Quantifying mammary duct carcinoma in situ : a wild-goose chase? Am J Clin Pathol 2000;113(5 Suppl. 1):S30–S37. 263. Grin A, Horne G, Ennis M, et al. Measuring extent of ductal carci- noma in situ in breast excision specimens: a comparison of 4 methods. Arch Pathol Lab Med 2009;133:31–37. 264. Marcotte-Bloch C, Balu-Maestro C, Chamorey E, et al. MRI for the size assessment of pure ductal carcinoma in situ (DCIS): a prospective study of 33 patients. Eur J Radiol 2011;77:462–467. 265. Thomas J, Evans A, Macartney J, et al. Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, speci- men handling and the influence on the success of breast conserva- tion surgery: a review of National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ ). Cancer 1995;75:1310–1319. 266. Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia of the breast. Cancer 1990;65:518–529. 267. Lagios MD, Westdahl PR, Margolin FR, et al. Duct carcinoma in situ . Relationship of extent of noninvasive disease to the frequency of oc- cult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982;50:1309–1314. 268. Lagios MD. Ductal carcinoma in situ : biological and therapeutic im- plications of classification. Breast J 1996;2:32–34. 269. Silverstein MJ, Cohlan BF, Gierson ED, et al. Duct carcinoma in situ : 227 cases without microinvasion. Eur J Cancer 1992;28:630–634. 270. Cheatle GL. Benign and malignant changes in duct epithelium of the breast. Br J Surg 1920/1921;8:285–306.